• Something wrong with this record ?

Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD

A. Vajsova, M. Cahova, L. Bajer, E. Sticova, I. Juskova, M. Hlavaty, O. Fabian

. 2025 ; 486 (4) : 651-661. [pub] 20250319

Language English Country Germany

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc25016248

Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree, leading to significant liver function impairment over time. There is a strong association with inflammatory bowel diseases (IBD), together representing a distinct and complex medical condition. Patients with PSC-IBD face a heightened risk of various cancers, particularly colorectal carcinoma (CRC) and cholangiocarcinoma (CCA) as the most common types. In this review, we aim to characterize the distinctive features of PSC-IBD-associated carcinomas. Cancer pathogenesis in PSC-IBD is shaped by various factors including dysregulated bile acid metabolism, gut dysbiosis, and unique immune responses. PSC-IBD-associated CRC is often right-sided and warrants vigilant monitoring due to its higher incidence and unique morphological features compared to CRC arising in the terrain of IBD alone. CCA shares substantial genetic similarities with extrahepatic CCA and poses diagnostic challenges since it is frequently detected at advanced stages due to symptom overlap with PSC. Besides, reliable predictive biomarkers for targeted therapy remain largely unexplored. The distinct molecular, genetic, and histopathological profiles of CRC and CCA in PSC-IBD underscore the complexity of these malignancies and highlight the need for continued research to develop precise therapeutic strategies.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016248
003      
CZ-PrNML
005      
20250731091633.0
007      
ta
008      
250708s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-025-04072-y $2 doi
035    __
$a (PubMed)40102272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Vajsova, Andrea $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic. andrea.vajsova@vfn.cz $u Institute of Pathology of the First Faculty of Medicine and General Teaching Hospital, Prague, 12800, Czech Republic. andrea.vajsova@vfn.cz $1 https://orcid.org/0000000284738664
245    10
$a Unique clinical, morphological, and molecular characteristics of tumors associated with PSC-IBD / $c A. Vajsova, M. Cahova, L. Bajer, E. Sticova, I. Juskova, M. Hlavaty, O. Fabian
520    9_
$a Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease characterized by chronic inflammation and progressive fibrosis of the biliary tree, leading to significant liver function impairment over time. There is a strong association with inflammatory bowel diseases (IBD), together representing a distinct and complex medical condition. Patients with PSC-IBD face a heightened risk of various cancers, particularly colorectal carcinoma (CRC) and cholangiocarcinoma (CCA) as the most common types. In this review, we aim to characterize the distinctive features of PSC-IBD-associated carcinomas. Cancer pathogenesis in PSC-IBD is shaped by various factors including dysregulated bile acid metabolism, gut dysbiosis, and unique immune responses. PSC-IBD-associated CRC is often right-sided and warrants vigilant monitoring due to its higher incidence and unique morphological features compared to CRC arising in the terrain of IBD alone. CCA shares substantial genetic similarities with extrahepatic CCA and poses diagnostic challenges since it is frequently detected at advanced stages due to symptom overlap with PSC. Besides, reliable predictive biomarkers for targeted therapy remain largely unexplored. The distinct molecular, genetic, and histopathological profiles of CRC and CCA in PSC-IBD underscore the complexity of these malignancies and highlight the need for continued research to develop precise therapeutic strategies.
650    _2
$a lidé $7 D006801
650    12
$a cholangiokarcinom $x patologie $x etiologie $x genetika $7 D018281
650    12
$a sklerozující cholangitida $x komplikace $x patologie $7 D015209
650    12
$a nádory žlučových cest $x patologie $x etiologie $x genetika $7 D001650
650    12
$a idiopatické střevní záněty $x komplikace $x patologie $7 D015212
650    12
$a kolorektální nádory $x patologie $x etiologie $x genetika $7 D015179
650    _2
$a nádorové biomarkery $x genetika $7 D014408
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Cahova, Monika $u Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic
700    1_
$a Bajer, Lukas $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, 14021 , Czech Republic $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, 15000, Czech Republic
700    1_
$a Sticova, Eva $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic $u Department of Pathology, Royal Vinohrady Teaching Hospital, Srobarova 1150/50, Prague, 10000, Czech Republic
700    1_
$a Juskova, Ivana $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic
700    1_
$a Hlavaty, Mojmir $u Department of Gastroenterology and Hepatology, Institute for Clinical and Experimental Medicine, Prague, 14021 , Czech Republic
700    1_
$a Fabian, Ondrej $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague, 14021, Czech Republic $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, Prague, 14059, Czech Republic
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 486, č. 4 (2025), s. 651-661
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40102272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091628 $b ABA008
999    __
$a ok $b bmc $g 2366826 $s 1253373
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 486 $c 4 $d 651-661 $e 20250319 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options